2. Search Result
Search Result
Results for "

arterial blood pressure

" in MedChemExpress (MCE) Product Catalog:

57

Inhibitors & Agonists

2

Biochemical Assay Reagents

3

Peptides

7

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D0227
    THAM
    1 Publications Verification

    Tris; Tris(hydroxymethyl)aminomethane

    		 Biochemical Assay Reagents Metabolic Disease
    THAM (Tris) is a low-toxicity amino alcohol buffer, a specific CO2-consuming proton acceptor that buffers carbon dioxide and acid both in vitro and in vivo. THAM binds protons to form bicarbonate, reduces PaCO2, and induces intracellular alkalization, thereby ameliorating hypercapnia-induced elevation of pulmonary blood vessels and pulmonary arterial pressure. THAM may cause PaCO2 rebound, hypoglycemia, and respiratory depression. THAM removes amniotic epithelium and preserves the basement membrane, but depletes extracellular matrix and reduces the adhesion rate of limbal epithelial cells. THAM can act as a CO2 carrier to enhance the productivity and carbon utilization rate of Scenedesmus obliquus. THAM is a key component of buffer solutions used in various biological, cell culture, biochemical, and molecular biology applications .
    THAM
  • HY-124489
    2-Hydroxyestradiol
    2 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity .
    2-Hydroxyestradiol
  • HY-112868B
    ABH hydrochloride
    1 Publications Verification

    		 Arginase NO Synthase Integrin Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    ABH (hydrochloride) is an orally active arginase inhibitor (Ki = 8.5 nM). ABH hydrochloride promotes NO production and reduces the expression of inflammatory response-related molecules (ICAM-1, VCAM-1, MCP-1). ABH hydrochloride improves erectile function, reduces lung damage, promotes wound healing, reduces arterial blood pressure, and improves vascular fibrosis .
    ABH hydrochloride
  • HY-B1470
    Azaperone

    R-1929

    		 Dopamine Receptor Adrenergic Receptor Neurological Disease
    Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent .
    Azaperone
  • HY-114794
    Desglymidodrine

    ST 1059

    		 Adrenergic Receptor Drug Metabolite Cardiovascular Disease
    Desglymidodrine (ST 1059), the active metabolite of Midodrine(HY-12749), is a selective α1-adrenoceptor agonist. Desglymidodrine is an effective arterial and venous vasoconstrictor and can be used to regulate blood pressure .
    Desglymidodrine
  • HY-107915
    Levonordefrin

    (-)-Cobefrin; (-)-α-Methylnoradrenaline; (-)-Nordefrin

    		 Adrenergic Receptor Cardiovascular Disease
    Levonordefrin ((-)-Cobefrin; (-)-α-Methylnoradrenaline; (-)-Nordefrin) is an α-adrenergic receptor agonist with blood pressure regulatory properties. Levonordefrin is a key metabolite responsible for the hypotensive effect of α-methyldopa. By stimulating central α-adrenergic receptors in the nucleus tractus solitarius region of the medulla oblongata, Levonordefrin induces centrally mediated hypotension and bradycardia. When administered intravenously, Levonordefrin increases mean arterial blood pressure in a dose-dependent manner. Levonordefrin is applicable for research on the pathophysiology of hypertension and drug metabolism .
    Levonordefrin
  • HY-120295
    A-192621
    2 Publications Verification

    		 Endothelin Receptor Apoptosis Cardiovascular Disease Endocrinology
    A-192621, a chemical probe, is a potent, nonpeptide, orally active and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. The selectivity of A-192621 is 636-fold higher than ETA (IC50 of 4280 nM and Ki of 5600 nM). A-192621 promotes apoptosis in PASMCs. A-192621 alos causes elevation of arterial blood pressure and an elevation in the plasma ET-1 level .
    A-192621
  • HY-D0227J
    THAM hydrochloride (≥99%, for cell culture)
    1 Publications Verification

    Tris HCl (≥99%, for cell culture); Tris hydrochloride (≥99%, for cell culture)

    		 Biochemical Assay Reagents Metabolic Disease
    THAM hydrochloride (≥99%, for cell culture) is a low-toxicity amino alcohol buffer, a specific CO2-consuming proton acceptor that buffers carbon dioxide and acid both in vitro and in vivo. THAM hydrochloride (≥99%, for cell culture) binds protons to form bicarbonate, reduces PaCO2, and induces intracellular alkalization, thereby ameliorating hypercapnia-induced elevation of pulmonary blood vessels and pulmonary arterial pressure. THAM hydrochloride (≥99%, for cell culture) may cause PaCO2 rebound, hypoglycemia, and respiratory depression. THAM hydrochloride (≥99%, for cell culture) removes amniotic epithelium and preserves the basement membrane, but depletes extracellular matrix and reduces the adhesion rate of limbal epithelial cells. THAM hydrochloride (≥99%, for cell culture) can act as a CO2 carrier to enhance the productivity and carbon utilization rate of Scenedesmus obliquus. THAM hydrochloride (≥99%, for cell culture) is a key component of buffer solutions used in various biological, cell culture, biochemical, and molecular biology applications .
    THAM hydrochloride (≥99%, for cell culture)
  • HY-14825A
    Tarafenacin D-tartrate

    SVT-40776 D-tartrate

    		 mAChR Inflammation/Immunology
    Tarafenacin (SVT-40776) D-tartrate is an orally active, selective M3 muscarinic receptor (M3 muscarinic receptor) antagonist with 203-fold selectivity over the M2 muscarinic receptor. Tarafenacin D-tartrate does not affect atrial contraction, arterial blood pressure or arterial pressure at high doses. Tarafenacin D-tartrate can be used in the research of overactive bladder .
    Tarafenacin D-tartrate
  • HY-W414915
    Valsartan methyl ester

    CGP 48933 methyl ester

    		 Drug Derivative Angiotensin Receptor Cardiovascular Disease Cancer
    Valsartan (CGP 48933) methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective and orally active angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .
    Valsartan methyl ester
  • HY-134061
    Arecaidine propargyl ester hydrobromide

    		Apoptosis Mitosis Cancer
    Arecaidine propargyl ester hydrobromide is an agonist of M2 muscarinic acetylcholine receptors and has the activity of inhibiting tumor cell proliferation. The application of arecaidine propargyl ester hydrobromide has shown that it can reduce the number of ovarian cancer cells in vitro and induce apoptosis and the production of reactive oxygen species (ROS) at specific concentrations. Arecaidine propargyl ester hydrobromide can also arrest cells at the G2/M phase of the cell cycle and increase the percentage of abnormal mitosis. Arecaidine propargyl ester hydrobromide is more sensitizing to ovarian surface epithelial cells with higher M2 receptor levels than to cancer cells. Arecaidine propargyl ester hydrobromide exhibits the effect of lowering arterial blood pressure when interacting with the cardiovascular system in a natural physiological state, indicating its potential pharmacological application .
    Arecaidine propargyl ester hydrobromide
  • HY-W016704
    2,5-Dihydroxybenzoic acid sodium

    Gentisic acid sodium

    		 Drug Derivative Cardiovascular Disease
    2,5-Dihydroxybenzoic acid (sodium) (Gentisic acid (sodium)) is a phenolic compound. 2,5-Dihydroxybenzoic acid (sodium) restores mean arterial pressure and reduces blood lactate concentration in animal models of sepsis and septic shock. 2,5-Dihydroxybenzoic acid (sodium) can be used in the study of septic shock related diseases .
    2,5-Dihydroxybenzoic acid sodium
  • HY-W153159
    N-Methyltyramine hydrochloride

    		Adrenergic Receptor Inflammation/Immunology
    N-Methyltyramine hydrochloride is an orally active α2-adrenoreceptor antagonist with an IC50 value of 5.53 μM against rat targets. N-Methyltyramine hydrochloride blocks α2-adrenoreceptors, while inhibiting lipolysis, hyperactivity responses and small intestinal peristalsis in mice. N-Methyltyramine hydrochloride promotes gastrin release and pancreatic juice secretion, upregulates appetite, blood pressure, myocardial contraction frequency and contraction intensity, and increases renal blood flow, renal vascular resistance and mean peripheral arterial resistance. N-Methyltyramine hydrochloride relaxes mouse small intestinal smooth muscle and undergoes biotransformation in vivo to produce adrenaline. N-Methyltyramine hydrochloride can be used in studies related to gastrointestinal diseases .
    N-Methyltyramine hydrochloride
  • HY-Y0537J
    Potassium chloride, meets analytical specification of Ph. Eur., BP, USP, FCC, E508, ≤0.0001% Al

    		Biochemical Assay Reagents Others
    Potassium chloride, meets analytical specification of Ph. Eur., BP, USP, FCC, E508, ≤0.0001% Al is a neutral potassium salt that can be used for buffer preparation, and can be used in biochemical research .
    Potassium chloride, meets analytical specification of Ph. Eur., BP, USP, FCC, E508, ≤0.0001% Al
  • HY-D0227B
    THAM acetate
    1 Publications Verification

    Tris acetate; Tris(hydroxymethyl)aminomethane acetate

    		 Biochemical Assay Reagents Metabolic Disease
    THAM acetate is a low-toxicity amino alcohol buffer, a CO2-consuming proton acceptor that buffers carbon dioxide and acid both in vitro and in vivo. THAM acetate binds protons to form bicarbonate, reduces PaCO2, and induces intracellular alkalization, thereby ameliorating hypercapnia-induced elevation of pulmonary blood vessels and pulmonary arterial pressure. THAM acetate may cause PaCO2 rebound, hypoglycemia, and respiratory depression. THAM acetate removes amniotic epithelium and preserves the basement membrane, but depletes extracellular matrix and reduces the adhesion rate of limbal epithelial cells. THAM acetate can act as a CO2 carrier to enhance the productivity and carbon utilization rate of Scenedesmus obliquus. THAM acetate is a key component of buffer solutions used in various biological, cell culture, biochemical, and molecular biology applications .
    THAM acetate
  • HY-119081
    GSK2181236A

    		Guanylate Cyclase Cardiovascular Disease
    GSK2181236A is a NO-insensitive soluble guanylate cyclase (sGC) activator. GSK2181236A can dilate blood vessels, decrease mean arterial pressure and attenuate the development of cardiac hypertrophy. GSK2181236A can be used for the research of cardiovascular disease, such as hypertension .
    GSK2181236A
  • HY-115269
    CK-2289

    		Phosphodiesterase (PDE) Cardiovascular Disease
    CK-2289 is an inhibitor of type III cyclic 3'5'-adenosine monophosphate phosphodiesterase (PDE). CK-2289 can inhibit platelet aggregation and decreases mean arterial blood pressure. CK-2289 can be used for the research of cardiovascular disease, such as congestive heart failure .
    CK-2289
  • HY-117928
    BRL 55834

    		Potassium Channel Cardiovascular Disease
    BRL 55834 is an orally and potent potassium channel activator. BRL 55834 exhibits great bronchodilator potency but reduces tendency to lower arterial blood pressure. BRL 55834 has the potential to use as a bronchodilator .
    BRL 55834
  • HY-A0184
    Remikiren

    Ro 42-5892; Ro 42-5892/001

    		 Renin Cardiovascular Disease
    Remikiren (Ro 42-5892) is an orally active and highly specific renin inhibitor. Remikiren specifically inhibits human reninand human plasma renin with IC50 values of 0.7 and 0.8 nM, respectively. Remikiren also reduces mean arterial blood pressure in sodium-depleted marmosets and squirrel monkeys. Remikiren can be used in study of hypertension .
    Remikiren
  • HY-116680
    LY53857

    		5-HT Receptor Cardiovascular Disease Neurological Disease
    LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT2 receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves .
    LY53857
  • HY-101554
    Guancydine

    Guancidine

    		 Adrenergic Receptor Cardiovascular Disease
    Guancydine (Guancidine) is an orally active antihypertensive agent and vasodilator. Guancydine antagonizes the pressor effects of Angiotensin and Norepinephrine (HY-13715). Guancydine induces vasodilation in renal, mesenteric and cranial vascular beds, reduces peripheral resistance, increases cardiac output and lowers arterial blood pressure. Guancydine increases renal and forearm blood flow, reduces renal and forearm vascular resistance, alters cardiac systolic time, and reverses myocardial hypertrophy in hypertensive rats. Guancydine is applicable for research related to hypertension .
    Guancydine
  • HY-117805
    UR-7247

    		Angiotensin Receptor Cardiovascular Disease
    UR-7247 is a potent and orally active angiotensin II AT1 receptor antagonist. UR-7247 decreases arterial pressure and increases renal blood flow .
    UR-7247
  • HY-A0114
    Moexiprilat

    RS 10029

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=2.1 nM) and an active metabolite of the prodrug Moexipril (HY-117281). It is formed from moexipril in vivo by side chain ester hydrolysis. Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts. It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.
    Moexiprilat
  • HY-N1115
    Tubotaiwine

    (+)-Tubotaiwine; NSC 306222; Tubotaiwin

    		 Others Cardiovascular Disease
    Tubotaiwine ((+)-Tubotaiwine), an alkaloid, has beneficial effect on cadmium (Cd) induced hypertension in rats. Tubotaiwine regulates systolic, diastolic and mean arterial blood pressure of the Cd exposed rats. Tubotaiwine reduces arterial stiffness, inhibits of oxidative stress and increases vascular remodeling .
    Tubotaiwine
  • HY-W153897
    N-Methyltyramine

    		Adrenergic Receptor Inflammation/Immunology
    N-Methyltyramine is an orally active α2-adrenoreceptor antagonist with an IC50 value of 5.53 μM against rat targets. N-Methyltyramine blocks α2-adrenoreceptors, while inhibiting lipolysis, hyperactivity responses and small intestinal peristalsis in mice. N-Methyltyramine promotes gastrin release and pancreatic juice secretion, upregulates appetite, blood pressure, myocardial contraction frequency and contraction intensity, and increases renal blood flow, renal vascular resistance and mean peripheral arterial resistance. N-Methyltyramine relaxes mouse small intestinal smooth muscle and undergoes biotransformation in vivo to produce adrenaline. N-Methyltyramine can be used in studies related to gastrointestinal diseases .
    N-Methyltyramine
  • HY-B1470S
    Azaperone-d4

    R-1929-d4

    		 Isotope-Labeled Compounds Dopamine Receptor Adrenergic Receptor Neurological Disease
    Azaperone-d4 (R-1929-d4) is the deuterium labeled Azaperone (HY-B1470). Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent.
    Azaperone-d4
  • HY-76652
    VTP-27999 (Hydrochloride)

    		Renin Cardiovascular Disease Inflammation/Immunology
    VTP-27999 Hydrochloride is an orally active renin inhibitor. VTP-27999 Hydrochloride functionally inhibits renin and acid-activated prorenin, suppresses plasma renin activity and modulates plasma and urinary aldosterone levels. VTP-27999 Hydrochloride reduces mean arterial blood pressure, induces plasma renin concentration increases, decreases plasma angiotensin II levels and enhances renin immunoreactivity. VTP-27999 (Hydrochloride) can be used for the research of hypertension and chronic renal disease .
    VTP-27999 (Hydrochloride)
  • HY-16506
    Trimethaphan camsylate

    Ro 2-2222; Thiophanium derivatives

    		 Adrenergic Receptor Cardiovascular Disease Others
    Trimethaphan camsylate is an arterial blood pressure lowering agent that has been shown to reduce pulmonary venous pressure in experimental pulmonary edema.
    Trimethaphan camsylate
  • HY-101733
    Zabicipril hydrochloride

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Zabicipril hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor. Zabicipril hydrochloride can be used for the study of blood pressure and peripheral arterial insufficiency .
    Zabicipril hydrochloride
  • HY-105266
    Zabicipril

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Zabicipril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Zabicipril can be used for the study of blood pressure and peripheral arterial insufficiency .
    Zabicipril
  • HY-14825
    Tarafenacin

    SVT-40776

    		 mAChR Inflammation/Immunology
    Tarafenacin (SVT-40776) is an orally active, selective M3 muscarinic receptor (M3 muscarinic receptor) antagonist with 203-fold selectivity over the M2 muscarinic receptor. Tarafenacin does not affect atrial contraction, arterial blood pressure or arterial pressure at high doses. Tarafenacin can be used in the research of overactive bladder .
    Tarafenacin
  • HY-107037
    Tolmesoxide

    RX71107

    		 Vasopressin Receptor Angiotensin Receptor Adrenergic Receptor Cardiovascular Disease
    Tolmesoxide (RX71107) is a peripheral vascular dilator with blood pressure lowering activity. Tolmesoxide has shown direct vasodilation in the human forearm arterial bed and dorsal hand vein. Tolmesoxide can dose-dependently increase blood flow in the forearm and produce dilation during contraction of the dorsal hand veins. Tolmesoxide can be used to study high blood pressure and angina .
    Tolmesoxide
  • HY-119291
    RA642

    		Phosphodiesterase (PDE) Others
    RA642 is a compound with vasodilatory and hypertensive effects, with the activity of increasing arterial blood pressure, enhancing cerebral blood flow, reducing cerebrovascular resistance and peripheral resistance, and having a papaverine-like relaxant effect on smooth muscle in anesthetized animals.
    RA642
  • HY-P3593
    LPLRF-NH2

    		Calcium Channel Cardiovascular Disease Neurological Disease
    LPLRF-NH2 is a member of RFamide peptide with anorexigenic effect. LPLRF-NH2 increases arterial blood pressure and modulates the electrical activity of brainstem neurons .
    LPLRF-NH2
  • HY-118033
    SQ 30774

    		Renin Cardiovascular Disease
    SQ 30774 is a renin (renin) inhibitor. SQ 30774 has potent in vitro inhibitory effects in primates but not in rats, pigs, or dogs. And imidazolinol renin inhibitors also inhibit PRA and reduce arterial blood pressure in vivo .
    SQ 30774
  • HY-105925
    Mefenidil

    MCN 2378

    		 Adrenergic Receptor Cardiovascular Disease
    Mefenidil (MCN 2378) is a selective cerebral vasodilator that is not affected by beta-adrenergic blockade. Mefenidil can be used in the study of cardiovascular disease. In monkey models, mefenidil preferentially increases cerebral blood flow over systemic (femoral) blood flow. Mefenidil is also able to reduce systemic arterial pressure in anesthetized dogs.
    Mefenidil
  • HY-18209
    Z-13752A

    		Neprilysin Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Z-13752A is a mercaptopropanoyl amino acid. Z-13752A inhibits NEP and ACE, with Ki values of 1.8 and 3.2 nM, respectively. Z-13752A decreases the arterial blood pressure and increases coronary blood flow. Z-13752A can be used in the research of coronary artery occlusion .
    Z-13752A
  • HY-135488
    A 131701

    		Adrenergic Receptor Cardiovascular Disease
    A 131701 is a selective α1a- (Ki: 0.22 nM for human α1a) and α1d-adrenoceptor antagonist. A 131701 antagonizes epinephrine-induced increases in intraurethral pressure (IUP). A 131701 causes transient decreases in mean arterial blood pressure (MABP) and transient tachycardia. A 131701 can be used in the research of spontaneous hypertension .
    A 131701
  • HY-P1694
    B4148

    		Bradykinin Receptor Cardiovascular Disease
    B4148 is a selective competitive bradykinin (BK) antagonist that significantly inhibits BK-induced hypotension in rats. In a rat model of endotoxin shock induced by Escherichia coli lipopolysaccharide, B4148 significantly attenuated the decrease in mean arterial blood pressure compared with the control group .
    B4148
  • HY-118185
    SQ 31844

    		Renin Others
    SQ 31844 is a novel renin inhibitor belonging to the imidazolidinol class. This compound, which contains an imidazole ring in its active site binding group, has potent in vitro inhibition of primate renin, but not rat, pig, or dog renin. In conscious, sodium-deprived cynomolgus monkeys, both compounds produced dose-related inhibition of plasma renin activity (PRA) over a dose range of 0.001 to 1.0 μmol/kg, administered intravenously, with complete inhibition observed at the highest dose. However, a reduction in blood pressure was only observed when 10 μmol/kg was administered intravenously or by infusion. In sodium-replete monkeys, SQ 30774 inhibited the increase in arterial blood pressure and PRA following administration of exogenous monkey renin. When the compounds were administered orally at 50 μmol/kg, only SQ 31844 significantly inhibited PRA (80%). In summary, the imidazolidinol renin inhibitors have potent inhibitory effects on renin in vitro and inhibit PRA and reduce arterial blood pressure in vivo.
    SQ 31844
  • HY-124489R
    2-Hydroxyestradiol (Standard)

    		Endogenous Metabolite Reference Standards Metabolic Disease
    2-Hydroxyestradiol (Standard) is the analytical standard of 2-Hydroxyestradiol. This product is intended for research and analytical applications. 2-Hydroxyestradiol, a metabolite of 17β-estradiol with minimal estrogenic activity, possesses antioxidant effects and reacts with DNA to form stable adducts and exerts genotoxicity .
    2-Hydroxyestradiol (Standard)
  • HY-114794R
    Desglymidodrine (Standard)

    ST 1059 (Standard)

    		 Reference Standards Adrenergic Receptor Drug Metabolite Cardiovascular Disease
    Desglymidodrine (Standard) is the analytical standard of Desglymidodrine. This product is intended for research and analytical applications. Desglymidodrine (ST 1059), the active metabolite of Midodrine(HY-12749), is a selective α1-adrenoceptor agonist. Desglymidodrine is an effective arterial and venous vasoconstrictor and can be used to regulate blood pressure .
    Desglymidodrine (Standard)
  • HY-107915R
    Levonordefrin (Standard)

    (-)-Cobefrin (Standard); (-)-α-Methylnoradrenaline (Standard); (-)-Nordefrin (Standard)

    		 Reference Standards Adrenergic Receptor Others
    Levonordefrin (Standard) is the analytical standard of Levonordefrin. This product is intended for research and analytical applications. Levonordefrin ((-)-Cobefrin; (-)-α-Methylnoradrenaline; (-)-Nordefrin) is an α-adrenergic receptor agonist with blood pressure regulatory properties. Levonordefrin is a key metabolite responsible for the hypotensive effect of α-methyldopa. By stimulating central α-adrenergic receptors in the nucleus tractus solitarius region of the medulla oblongata, Levonordefrin induces centrally mediated hypotension and bradycardia. When administered intravenously, Levonordefrin increases mean arterial blood pressure in a dose-dependent manner. Levonordefrin is applicable for research on the pathophysiology of hypertension and drug metabolism .
    Levonordefrin (Standard)
  • HY-136625
    LY134046

    		N-myristoyltransferase Cardiovascular Disease
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT) with cardiovascular activity. LY134046 causes sustained reductions in mean arterial blood pressure and heart rate, but no significant reductions in norepinephrine concentrations in the rat brain. LY134046 does not interact with adrenergic or cholinergic receptors, and its hypotensive and bradycardic effects do not require neurogenic tension. LY134046 (40 mg/kg/day) causes sustained and significant inhibition of hypothalamic and brainstem NMT activity, resulting in central norepinephrine depletion.
    LY134046
  • HY-113858
    Brefonalol

    Brefanolol

    		 Adrenergic Receptor Cardiovascular Disease
    Brefonalol (Brefanolol) is an orally active, non-selective β-adrenergic receptor blocker with vasodilatory properties. Brefonalol exhibits an optimal balance between β-blockade and vasodilatory effects at low doses: it reduces blood pressure and slows heart rate, while increasing stroke volume instead of decreasing it, causing no significant elevation in peripheral resistance and increasing reactive hyperemia; at high doses, the β-blockade effect dominates. Brefonalol can be used in the research of arterial hypertension .
    Brefonalol
  • HY-122300B
    R-(-)-Oxaprotiline

    Levoprotiline

    		 Adrenergic Receptor Neurological Disease
    R-(-)-Oxaprotiline (Levoprotiline) is an antidepressant with anticholinergic and sympathostimulatory activities. R-(-)-Oxaprotiline exhibits different abilities to block norepinephrine uptake and anticholinergic activity compared to its enantiomer C 49802 B-Ba. R-(-)-Oxaprotiline in human studies shows physiological effects consistent with those in animals. Administration of R-(-)-Oxaprotiline results in a modest increase in heart rate and arterial blood pressure. Salivation is inhibited with R-(-)-Oxaprotiline, consistent with its anticholinergic properties. R-(-)-Oxaprotiline has similar effects to the established antidepressant compound Levoprotiline and has a shorter onset of action .
    R-(-)-Oxaprotiline
  • HY-171469
    SKP-451

    		Potassium Channel Cardiovascular Disease
    SKP-451 is an ATP-sensitive potassium (K +) channel agonist. SKP-451 activates the ATP-sensitive K + channels, promotes the efflux of K +, causes membrane hyperpolarization, and inhibits the influx of Ca 2+, thereby relaxing the vascular smooth muscle. SKP-451 relaxs the canine coronary artery, rabbit basilar artery, and vertebral artery. SKP-451 also reduces the mean arterial blood pressure of conscious spontaneously hypertensive rats (SHR). SKP-451 is promising for research of cardiovascular diseases .
    SKP-451
  • HY-B1470R
    Azaperone (Standard)

    R-1929 (Standard)

    		 Reference Standards Dopamine Receptor Adrenergic Receptor Neurological Disease
    Azaperone (R-1929) (Standard) is the analytical standard of Azaperone (HY-B1470). This product is intended for research and analytical applications. Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent.
    Azaperone (Standard)
  • HY-W153897R
    N-Methyltyramine (Standard)

    		Reference Standards Adrenergic Receptor Inflammation/Immunology
    N-Methyltyramine (Standard) is the analytical standard of N-Methyltyramine (HY-W153897). This product is intended for research and analytical applications. N-Methyltyramine is an orally active α2-adrenoreceptor antagonist with an IC50 value of 5.53 μM against rat targets. N-Methyltyramine blocks α2-adrenoreceptors, while inhibiting lipolysis, hyperactivity responses and small intestinal peristalsis in mice. N-Methyltyramine promotes gastrin release and pancreatic juice secretion, upregulates appetite, blood pressure, myocardial contraction frequency and contraction intensity, and increases renal blood flow, renal vascular resistance and mean peripheral arterial resistance. N-Methyltyramine relaxes mouse small intestinal smooth muscle and undergoes biotransformation in vivo to produce adrenaline. N-Methyltyramine can be used in studies related to gastrointestinal diseases .
    N-Methyltyramine (Standard)
  • HY-W414915R
    Valsartan methyl ester (Standard)

    CGP 48933 methyl ester (Standard)

    		 Reference Standards Drug Derivative Angiotensin Receptor Cardiovascular Disease
    Valsartan (CGP 48933) methyl ester (Standard) is the analytical standard of Valsartan methyl ester (HY-W414915). This product is intended for research and analytical applications. Valsartan methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .
    Valsartan methyl ester (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: